Jason McCarl, MD
Pulmonary Disease · Greeley, CONPI 1144376757
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,075 of the $2,824 with a category attached, or 73.5%. Boehringer Ingelheim accounts for 96.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $2,302 and has fallen 91.1% since, to $205 in 2025.
Across 10 payments — averaging $282.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- AstraZeneca$96
- Gilead$14
Across 12 payments — averaging $23,171 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$278K
What the payments were for
- Consulting fees$2,07573%
- Food & beverage$63923%
- Education$1104%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $2,714 |
| AstraZeneca | 1 | $96 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$2,316
How this compares
$2,824 in reported general payments places this provider in the 65th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 18 | $251,429 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 219 | $173,416 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 96 | $68,825 |
| Fasenra PenBenralizumab | 11 | $65,810 |
| Dupixent PenDupilumab | 13 | $48,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $43,547 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $32,526 |
| Spiriva RespimatTiotropium Bromide | 44 | $28,171 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $25,014 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $22,822 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $13,506 |
| BreynaBudesonide/Formoterol Fumarate | 55 | $12,950 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $11,645 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $8,189 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $2,714 | $355,535173 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $96 | $204,427306 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Greeley
- Bryan McVayGreeley$14K
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Joshiah GordonPueblo$208K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.